We have previously demonstrated the presence of gonadotropin-releasing hormone (Gn-RH) messenger ribonucleic acid (mRNA) in epithelial ovarian carcinoma. In this study, the expression of Gn-RH receptor (Gn-RHR) was investigated in human ovarian carcinoma and human ovarian carcinoma cell line. Gn-RHR was determined by [3H] Gn-RH binding assay. Gn-RHR mRNA was determined by reverse transcription-polymerase chain reaction using oligonucleotide primers synthesized based on published human Gn-RHR sequence.
Specific Gn-RH binding sites were shown to be present in plasma membrane isolated from five ovarian mucinous cystadenocarcinoma samples and one serous cystadenocarcinoma (Kd = 15·3 ± 8·08 nmol/L). Gn-RHR mRNA was detected in four mucinous cystadenocarcinoma specimens, one serous cystadenocarcinoma, and SK-OV-3 cells, but not in white blood cells. These results suggest that Gn-RH may play an autocrine regulatory role in the growth of ovarian carcinoma.
ImaiAFuruiTTamayaT. Is extrapituitary action of gonadotropin-releasing hormone biologically significant?Ann Clin Biochem1992; 29: 477–80.
2.
EmonsGOrtmannOPahwaGSHackenbergROberheuserFSchulzKD. Intracellular actions of gonadotropin and peptide hormones and the therapeutic value of GnRH-agonist in ovarian cancer. Acta Obstet Gynecol Scand1992; 71: 31–8.
3.
SchallyAV. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med1984; 175: 259–81.
4.
ManniASantenRHarveyHLiptonAMaxD. Treatment of breast cancer with gonadotropin-releasing hormone. Endocr Rev1986; 7: 89–113.
5.
SherwoodNMLovejoyDACoeIR. Origin of mammalian gonadotropin-releasing hormones. Endocr Rev1993; 17: 241–54.
6.
HarrisNDutlowCEidneKDongKWRobertsJMillarR. Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell line. Cancer Res1991; 51: 2577–81.
7.
OhnoTImaiAFuruiTTakahashiKTamayaT. Presence of gonadotropin-releasing hormone and its messenger ribonucleic acid in human epithelial ovarian carcinoma. Am J Obstet Gynecol1993; 169: 605–10.
8.
EmonsGPahmaGSBrackCSturmROberheuserFKnuppenR. Gonadotropin-releasing hormone binding sites in human epithelial ovarian carcinoma. Eur J Cancer Clin Oncol1989; 25: 215–21.
9.
PahwaGSVollmerGKnuppenREmonsG. Photoaffinity labelling of gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Biochem Biophys Res Commun1989; 161: 1086–92.
10.
ImaiAOhnoTFuruiTTakahashiKTamayaT. Gonadotropin-releasing hormone stimulates phospholipase C but not protein phosphorylation/dephosphorylation in plasma membrane from human epithelial ovarian cancer. Int J Gynecol Cancer1993; 3: 311–17.
11.
ParmarHNicollJStockdaleACassoniAPhillipsRHLightmanSLSchallyAV. Advanced ovarian carcinoma: Response to the agonist D-Trp6-LH-RH. Cancer Treat Rep1985; 69: 1341–2.
12.
ParmarHRustinGLightmanSLPhillipsRHHanhamIWSchallyAV. Response to D-Try-6-luteinizing hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. BMJ1988; 296: 1229.
13.
ParmarHPhillipsRHRustinFLightmanSLSchallyAV. Therapy of advanced ovarian cancer with D-Trp6-LH-RH (decapeptyl) microcapsules. Biomed Pharmacother1988; 42: 531–8.
14.
JägerWWildtLLangN. Some observations on the effects of a GnRH analogue in ovarian cancer. Eur J Obstet Gynecol Reprod Biol1989; 32: 137–48.
15.
KavanaghJJRobertsWTownsendPHewittS. Leuproid acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol1989; 7: 115–18.
16.
BrucknerHWMotwaniBT. Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Am J Obstet Gynecol1989; 161: 1216–18.
PetersonCMZimniskiSJ. A long acting gonadotropin-releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mouse. Obstet Gynecol1990; 76: 264–7.
19.
PourPMReddingTWPaz-BouzaJISchallyAV. Treatment of experimental ovarian carcinoma with monthly injection of the agonist D-Trp6-LH-RH: a preliminary report. Cancer Lett1988; 41: 105–10.
20.
MortelRSatyaswaroopPGSchallyAVHamiltonTOzolsR. Inhibitory effect of Gn-RH superagonist on the growth of human ovarian carcinoma. NIH: OV-CAR 3 in the nude mouse. Gynecol Oncol1986; 23: 254–65.
21.
ImaiARebecchiMJGershengornMC. Differential regulation by phosphatidyl-inositol 4,5-bisphosphate of pituitary plasma membrane and cytosolic phosphoinositide kinases. Biochem J1986; 240: 341–8.
22.
ImaiAGershengornMC. Independent phosphatidyl-inositol synthesis in rat pituitary plasma membrane and endoplasmic reticulum. Nature1987; 325: 725–8.
23.
EvansWH. Laboratory Techniques In Biochemistry and Molecular Biology, Vol. VII. New York: Elsevier, 1980: 103.
24.
LowryOHRosenbroughNJFarrALRandallRJ. Protein measurement with the Folin phenol reagent. J Biol Chem1951; 193: 265–75.
25.
ImaiAGershengornMC. Evidence for tight coupling of thyrotropin-releasing hormone receptors to stimulated inositol trisphosphate formation in rat pituitary cells. J Biol Chem1986; 260: 10536–40.
26.
ChomczynskiPSacchiN. Single-step method of RNA isolation by acid guanidinium thiocyanate-chloroform extraction. Anal Biochem1987; 162: 156–9.
27.
AvivHLederP. Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proc Natl Acad Sci USA1972; 69: 1408–12.
28.
WitsellALSchookLB. Clonal analysis of gene expression by PCR. Biotechniques1990; 9: 318–22.
29.
ChiLZhouWPrikhozhanAFlanaganCDavidsonJSGolemboMIllingNMillarRPSealfonSC. Cloning and characterization of the human GnRH receptor. Mol Cell Endocrinol1993; 91: R1–R6.
30.
SangerFSNicklenSCoulsonAR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA1977; 75: 5463–7.
31.
EidneKAFlanaganCAHarrisNSMillarRP. Gonadotropin-releasing hormone (Gn-RH)-binding sites in human breast cancer cell lines and inhibitory effects of Gn-RH antagonists. J Clin Endocrinol Metab1987; 64: 425–32.
32.
FeketeMBajuszSGrootKCsernusVJSchallyAV. Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membrane. Endocrinology1989; 124: 946–55.
33.
FeketeMReddingTWComaru-SchallyAMPontesJEConnellyRWSrkalovicGSchallyAV. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin and epidermal growth factor in cat and human prostate cancers and in benign prostate hyperplasia. Prostate1989; 14: 191–208.
34.
KadarTBen-DavidMPontesJEFeketeMSchallyAV. Prolactin and luteinizing hormone-releasing hormone receptors in human benign prostatic hyperplasia and prostate cancer. Prostate1988; 12: 299–307.
35.
LiebowCReillyCSerranoMSchallyAV. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA1989; 86: 2003–7.
36.
BelisleSGuevinJFBellabarbaDLehouxJG. Luteinizing hormone-releasing hormone binds to enriched human placental membranes and stimulates in vitro the synthesis of bioactive human chorionic gonadotropin. J Clin Endocrinol Metab1984; 59: 119–24.
37.
IwashitaMEvansMICattKJ. Characterization of a gonadotropin-releasing hormone receptor site in term placenta and chorionic villi. J Clin Endocrinol Metab1986; 62: 127–34.
38.
PopkinRBramleyTACurrieAShawRWBairdDTFraserHM. Specific binding of luteinizing hormone releasing hormone to human luteal tissue. Biochem Biophys Res Commun1983; 114: 750–6.
39.
BramleyTAManziesGSBairdDT. Specific binding of gonadotropin releasing hormone and an agonist to human corpus luteum homogenates: Characterization, properties, and luteal phase levels. J Clin Endocrinol Metab1985; 61: 834–41.
40.
CurrieAJFraserHMSharpeRM. Human placental receptors for luteinizing hormone releasing hormone. Biochem Biophys Res Commun1981; 99: 332–8.
41.
HirotaKHirotaTAguileraGCattKJ. Hormone-induced redistribution of calcium-activated phospholipid-dependent protein kinase in pituitary gonadotrophs. J Biol Chem1985; 260: 3243–6.
42.
ImaiAIidaKTamayaT. Tight coupling of gonadotropin-releasing hormone receptor to stimulated phosphoinositide turnover and anti-gonadotropic action in granulosa cells. Gynecol Obstet Invest1992; 33: 36–41.
